aripiprazole has been researched along with Substance-Related Disorders in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Czoty, PW; John, WS; Keck, TM; Nader, MA; Newman, AH | 1 |
| Boucher, M; Clerzius, G; Margolese, HC; Therrien, F | 1 |
| Foreman, K; Loh, R; Thurstone, C; Thurstone, CA; Wolf, C | 1 |
| Bulatova, RA; Ezhkova, EV; Ivanets, NN; Titkov, MS; Vinnikova, MA | 1 |
| Bennett, JA; Lile, JA; Rush, CR; Sevak, RJ; Stoops, WW | 1 |
| Calabrò, G; Caloro, M; Cuomo, I; De Filippis, S; Girardi, P; Kotzalidis, GD; Ranieri, V; Telesforo, CL; Zingaretti, P | 1 |
| Caballero, AR; Martínez, JS | 1 |
| Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
| Anderson, SJ; Brady, KT; McRae, AL; Tolliver, BK; Verduin, ML | 1 |
| Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W | 1 |
| Bergman, J | 1 |
| Lai, CH | 1 |
| Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW | 1 |
| Cottencin, O; Geoffroy, PA; Goddefroy, G; Rolland, B | 1 |
| Brunetti, M; Dezi, S; Di Tizio, L; Grandinetti, P; Martinotti, G; Pozzi, G | 1 |
| Gyertyán, I; Kiss, B; Román, V; Sághy, K; Szombathelyi, Z | 1 |
| Beard, L; Brown, ES; Garza, M; Jeffress, J; Liggin, JD | 1 |
| Glaser, PE; Lile, JA; Rush, CR; Stoops, WW | 1 |
| Kantrowitz, JT; Srihari, VH; Tek, C | 1 |
| Arnold, KK; Yager, J | 1 |
| Gardner, TJ; Kosten, TR | 1 |
4 review(s) available for aripiprazole and Substance-Related Disorders
| Article | Year |
|---|---|
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome | 2008 |
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug Therapy; Humans; Lobeline; Methamphetamine; Methylphenidate; Narcotic Antagonists; Nicotinic Agonists; Piperazines; Prevalence; Quinolones; Recurrence; Substance-Related Disorders | 2008 |
Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Dopamine Agonists; Drug Evaluation, Preclinical; Haplorhini; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Self Administration; Substance-Related Disorders | 2008 |
Aripiprazole, alcohol and substance abuse: a review.
Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Humans; Piperazines; Quinolones; Substance-Related Disorders; Tobacco Use Disorder | 2012 |
2 trial(s) available for aripiprazole and Substance-Related Disorders
| Article | Year |
|---|---|
[Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction].
Topics: Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Dibenzothiazepines; Humans; Male; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Substance-Related Disorders; Treatment Outcome | 2019 |
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Dopamine Agonists; Female; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substance-Related Disorders; Treatment Outcome | 2005 |
15 other study(ies) available for aripiprazole and Substance-Related Disorders
| Article | Year |
|---|---|
Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Topics: Animals; Central Nervous System Stimulants; Drug Discovery; Humans; Molecular Targeted Therapy; Receptors, Dopamine D3; Substance-Related Disorders | 2015 |
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.
Topics: Aripiprazole; Canada; Humans; Prospective Studies; Schizophrenia; Substance-Related Disorders | 2022 |
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
Topics: Adolescent; Adolescent, Hospitalized; Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Program Evaluation; Psychotic Disorders; Retrospective Studies; Risperidone; Substance-Related Disorders | 2023 |
Influence of aripiprazole pretreatment on the reinforcing effects of methamphetamine in humans.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Methamphetamine; Piperazines; Quinolones; Reinforcement, Psychology; Self Administration; Substance-Related Disorders; Surveys and Questionnaires; Young Adult | 2013 |
Hiccup with aripiprazole plus benzodiazepines resolving with pregabalin and/or benzodiazepine switch/discontinuation: four case reports.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Calcium Channel Blockers; Hiccup; Humans; Male; Marijuana Abuse; Pregabalin; Psychoses, Substance-Induced; Psychotic Disorders; Substance-Related Disorders; Young Adult | 2015 |
Long-Acting Aripiprazole in Comorbid Bipolar Disorder and Borderline Personality Disorder and Substance Abuse.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Borderline Personality Disorder; Comorbidity; Humans; Male; Substance-Related Disorders | 2017 |
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Humans; Hypertriglyceridemia; Mental Disorders; Piperazines; Quinolones; Substance-Related Disorders; Triglycerides; Weight Gain | 2008 |
Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Substance-Related Disorders | 2010 |
Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Behavior; Blood Pressure; Cardiovascular System; Central Nervous System Stimulants; Cocaine; Dextroamphetamine; Discrimination Learning; Female; Heart Rate; Humans; Male; Middle Aged; Piperazines; Quinolones; Substance-Related Disorders; Surveys and Questionnaires | 2011 |
Efficacy of aripiprazole in comorbid addiction in bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Male; Piperazines; Quinolones; Substance-Related Disorders; Treatment Outcome | 2012 |
Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Piperazines; Quinolones; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Secondary Prevention; Substance-Related Disorders | 2013 |
A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Pressure; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Piperazines; Quinolones; Substance-Related Disorders; Surveys and Questionnaires | 2006 |
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Remission Induction; Schizophrenia; Substance-Related Disorders | 2007 |
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Ephedrine; Feeding and Eating Disorders; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2007 |
Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Brain; Cocaine-Related Disorders; Diffusion Magnetic Resonance Imaging; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Piperazines; Quinolones; Substance-Related Disorders | 2007 |